相关实验视频

Updated: Jan 18, 2026

Protocols for Vaginal Inoculation and Sample Collection in the Experimental Mouse Model of Candida vaginitis

Protocols for Vaginal Inoculation and Sample Collection in the Experimental Mouse Model of Candida vaginitis

Published on: December 8, 2011

基于聚合物的尿-聚乙烯混合体阴道卵子,用于治疗 vulvovaginal candidiasis 的联合治疗

Brenda Maria Silva Bezerra¹, Kaidy G Orellana², Chen Sun²

¹Graduate Program in Pharmaceutical Sciences, Center for Biological and Health Sciences, State University of Paraíba, Av. Juvêncio Arruda, S/N, Campina Grande, Paraíba, 58429-500, Brazil.

Drug delivery and translational research

|May 28, 2025

概括

这项研究开发了生物相容的尿素多聚氧化物 (U-PPO400) 阴道卵子,用于治疗 vulvovaginal candidiasis (VVC). 卵子有效地释放了抗真菌药物,并显示出对Candida菌株的承诺.

科学领域:

生物材料科学生物材料科学
药理学药理学是指药理学的学科.
菌类学菌类学是指菌类学.

背景情况:

Vulvovaginal candidiasis (VVC) 是一种常见的感染,由Candida物种引起.
目前的治疗方法在有效性和使用频率上可能存在局限性.
开发新型药物输送系统对于改善VVC管理至关重要.

研究的目的:

开发和表征尿素多氧化 (U-PPO400) 阴道卵子用于修改药物释放.
评估U-PPO400含有米可纳 (MCZ) 和黄素 (CUR) 的卵子的生物相容性和抗真菌功效.
评估CUR和MCZ对Candida albicans和非白虫 (NAC) 菌株的协同作用.

主要方法:

使用sol-gel工艺合成了U-PPO400卵子.
评估了药物释放动力学,药物辅助剂兼容性 (H NMR,XRD,SEM) 和抗真菌活性.
通过阴道微生物群影响,细胞毒性测试 (VK2 / E6E7细胞) 和炎症反应评估来评估生物相容性.

主要成果:

在6天的时间里,U-PPO400卵子成功地结合并释放了MCZ (60.95%) 和CUR (12.06%).
CUR/MCZ组合显示了对NAC菌株的协同/添加效应,降低了最小抑制度.
U-PPO400显示出良好的生物相容性,没有对Lactobacillus jensenii产生负面影响,也没有白卵子的细胞毒性作用.

结论:

U-PPO400是一种有前途的生物相容基因,用于开发经过修改释放的阴道卵子.
CUR/MCZ组合为VVC提供了潜在的更有效的治疗策略,特别是针对NAC菌株.
这些卵子可以减少治疗频率并改善VVC管理结果.

关键词:

有控制释放的释放.其他非白虫Candida.有机无机材料有机无机材料协同作用协同作用协同作用通过阴道输送药物.

更多相关视频

Combination of High Ligation and Intraoperative Embolization using Polidocanol for Treatment of Varicoceles

Combination of High Ligation and Intraoperative Embolization using Polidocanol for Treatment of Varicoceles

Published on: December 22, 2023

Synthesis of Soft Polysiloxane-urea Elastomers for Intraocular Lens Application

Synthesis of Soft Polysiloxane-urea Elastomers for Intraocular Lens Application

Published on: March 8, 2019

相关概念视频

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...

Drugs for Treatment of Diarrhea-Predominant IBS

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

Combined Effects of Drugs: Synergism

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...

Drugs for Treatment of Constipation-Predominant IBS

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...